Sunday 18 October 2026
Export NXL’s income statement to Excel — free account
Nexalin Technology, Inc.
NXL Healthcare Medical Devices
Nexalin Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $301,600.00, up 78.8% from fiscal 2024. In the quarter to June 2026, revenue fell 82.7%, EPS fell 10.0% and free cash flow fell 97.2%, each against the same quarter a year earlier.
2.35
0.10
−4.08%
Follow NXL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
32.09 | 25.00 | 30.30 | 103.89 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.87) | (4.02) | (7.96) | (11.12) | |
P/B ratio |
4.59 | 2.39 | 2.44 | 3.42 | |
Price to Tangible BV |
16.60 | 2.73 | 2.68 | 3.65 | |
EV/Sales |
27.49 | 15.19 | 17.97 | 76.18 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.97) | (0.80) | (1.09) | (2.42) | |
EV/FCF |
(0.94) | (0.76) | (0.45) | (1.00) | |
Quick Ratio |
0.71 | 3.40 | 4.29 | 12.20 | |
Current Ratio |
1.25 | 4.07 | 4.85 | 13.48 | |
Net Debt/EBITDA |
0.45 | 1.28 | 1.55 | 1.86 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.05 | 0.08 | 0.07 | 0.03 | |
Operating CF/Net income |
0.80 | 0.82 | 0.48 | 0.64 | |
Capex/Depreciation |
(2.07) | (7.34) | (5.52) | (3.47) | |
Interest Coverage |
(22,473.00) | — | 206.26 | 1,019.83 | |
Research and Development Expense of Revenue |
4,627.05% | 2,309.33% | 130.83% | 1,251.38% | |
Selling, General and Administrative Expense of Revenue |
13,866.39% | 11,911.33% | 1,360.73% | 11,786.19% | |
Intangible Assets out of Total Assets |
0.37 | 0.10 | 0.07 | 0.06 | |
Share Based Compensation of Revenue |
3,347.54% | 3,190.67% | 483.77% | 5,982.32% | |
Graham Net Nets |
0.05 | 0.36 | 0.37 | 0.27 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(145.60%) | (135.19%) | (91.49%) | (72.05%) | |
Free Cash Flow Yield |
(90.92%) | (80.14%) | (131.04%) | (73.27%) | |
Revenue per Share |
0.02 | 0.02 | 0.31 | 0.03 | |
Operating CF per Share |
(2.56) | (2.60) | (2.10) | (2.47) | |
Capex per Share |
(0.07) | (0.12) | (0.06) | (0.03) | |
Free Cash Flow per Share |
(2.63) | (2.72) | (2.16) | (2.51) | |
Cash per Share |
1.43 | 4.10 | 6.82 | 7.35 | |
Shareholders Equity per Share |
2.16 | 4.37 | 6.87 | 8.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.16 | 4.37 | 6.87 | 8.05 | |
Free Cash Flow |
(1.85) | (1.79) | (1.18) | (1.49) | |
Working Capital |
0.38 | 2.48 | 3.41 | 4.46 | |
Capital Expenditures |
(0.05) | (0.08) | (0.03) | (0.02) | |
Net Current Asset Value |
0.38 | 2.48 | 3.41 | 4.46 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
3.92 | 5.29 | 0.20 | 1.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.06 | 0.03 | 0.05 | 0.01 | |
Average Payables |
0.24 | 0.17 | 0.20 | 0.12 | |
Average Inventory |
0.20 | 0.18 | 0.15 | 0.16 | |
Average Assets |
4.78 | 3.30 | 4.43 | 5.19 | |
Average Common Equity |
3.74 | 2.61 | 3.71 | 4.86 |
Columns are period end dates · fundamentals updated 2 Oct 2026